Overview

A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-08-23

Target enrollment:

Participant gender:

Summary

This study is a phase Ib/II study to evaluate the efficacy, safety and tolerance of HLX43 combined with HLX07 or Serplulimab in patients with advanced or metastatic colorectal cancer failed or intolerance to standard first-line therapy

Phase:

PHASE1

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

HLX07